Transcriptional regulation of Cyclooxygenase-2 gene expression: Novel effects of nonsteroidal anti-inflammatory drugs

Cancer Research

Volumn 60, Issue 4, 2000, Pages 1084-1091

  Yuan, Chiun Jye ^a   Mandal, Asim K ^a   Zhang, Zhongjian ^a   Mukherjee, Anil B ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CCAAT ENHANCER BINDING PROTEIN; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN; SULINDAC;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER MORTALITY; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME MECHANISM; ENZYME SUBSTRATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

3T3 CELLS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CCAAT-ENHANCER-BINDING PROTEINS; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOENZYMES; MICE; NUCLEAR PROTEINS; PHOSPHOLIPASES A; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TRANSCRIPTION, GENETIC;

EID: 0034652581     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Vane, J. R. Towards better aspirin. Nature (Lond.), 367: 215-216, 1994.
2. Meade, E. A., Smith, W. L., and DeWitt, D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 268: 6610-6614, 1993.
3. Smith, W. L., Garavito, R. M., and DeWitt, D. L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem., 271: 33157-33160, 1996.
4. Gierse, J. K., Hauser, S. D., Creely, D. P., Koboldt, C., Rangwala, S. H., Isakson, P. C., and Seibert, K. Expression and selective inhibition of the constitutive and inducible forms of cyclo-oxygenase. Biochem. J., 305: 479-484, 1995.
5. DeWitt, D. L., and Smith, W. L. Yes, but do they still get headaches? Cell, 83: 345-348, 1995.
6. Prescott, S. M., and White, R. L. Self-promotion? Intimate connections between APC and prostaglandin H synthase. Cell, 87: 783-786, 1996.
7. Thun, M. J., Namboodiri, M. M., and Heath, C. J. N. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
8. Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333: 609-614, 1995.
9. Boolbol, S. K., Danenberg, A. J., Chadburn, A., Martucci, C., Guo, X., Ramonetti, J. T., Areu-Goris, M., Newmark, H. L., Lepkin, M. L., DeCosse, J. J., and Bertagnolli, M. M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of FAP. Cancer Res., 56: 2556-2560, 1996.
10. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
11. Sheng, G. G., Shao, J., Sheng, H., Hooton, E. B., Isakson, P. C., Morrow, J. D., Coffey, R. J., DuBois, R. N., and Beauchamp, R. D. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology, 113: 1883-1891, 1997.
12. Elder, D. J. E., and Paraseva, C. NSAIDs to prevent colorectal cancer: a question of sensitivity. Gastroenterology, 113: 1999-2008, 1997.
13. Elder, D. J. E., and Paraskeva, C. COX-2 inhibitors for colorectal cancer. Nat. Med., 4: 392-393, 1998.
14. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
15. Waite, M. In: D. J. Hanahan (ed.), The Phospholipases, pp. 1-332. New York: Plenum Publishing Corp., 1998.
16. 2. Crit. Rev. Immunol., 17: 225-283, 1997.
17. 2 gene family in mammals. J. Biol. Chem., 272: 17247-17250, 1997.
18. 2 receptor. J. Biol. Chem., 269: 5897-5904, 1994.
19. 2. J. Biol. Chem., 269: 1575-1578, 1994.
20. 2 stimulates prostaglandin synthesis in mouse osteoblastic cells (MC3T3E1) via a specific binding site. J. Biol. Chem., 268: 2865-2871, 1993.
21. 2 expression and prostaglandin biosynthesis in rat mesangial cells. J. Biol. Chem., 269: 5092-5098, 1994.
22. 2 are natural ligands of the mouse 180-kDa M-type receptor. J. Biol. Chem., 274: 7043-7051, 1999.
23. 2 in the rat. J. Biol. Chem., 267: 6414-6420, 1992.
24. Ledwith, B. J., Pauley, C. J., Wagner, L. K., Rokos, C. L., Alberts, D. W., and Manam, S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol-12,13-myristate-type tumor promoters in immortalized mouse liver cells. J. Biol. Chem., 272: 3707-3714, 1997.
25. 2 in rat chondrocyte via its specific binding sites. Biochem. Biophys. Res. Commun., 186: 1025-1031, 1992.
26. 2, is mediated via its specific receptor but not via its catalytic property. Int. J. Oncol., 9: 1219-1225, 1996.
27. 2 stimulates the growth of human pancreatic cancer cell line. FEBS Lett., 373: 85-87, 1995.
28. 2-induced contraction of guinea pig lung pleural strips. Eur. J. Pharmacol., 216: 87-96, 1992.
29. 2 on isolated porcine cerebral arteries via its specific binding sites. FEBS Lett., 309: 261-264, 1992.
30. 2 via specific binding sites. Biochim. Biophys. Acta, 1125: 210-214, 1992.
31. 2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells. J. Biol. Chem., 272: 2346-2353, 1997.
32. Wedel, A., and Ziegler-Heibrock, H. W. L. The C/EBP family of transcription factors. Immunobiology, 193: 171-185, 1995.
33. Poli, V., Mancini, F. P., and Cortese, R. IL-6 DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell, 63: 643-653, 1990.
34. Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., and McKnight, S. L. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev., 2: 785-795, 1988.
35. Descombes, P., Chojkier, M., Lichtsteiner, S., Falvey, E., and Schibler, U. LAP, a novel member of the C/EBP gene family, encodes a liver-enriched transcriptional activator protein. Genes Dev., 4: 1541-1551, 1990.
36. Cao, Z., Umek, R. M., and McKnight, S. L. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev., 5: 1538-1553, 1991.
37. Birkenmeier, E. H., Gwynn, B., Howard, S., Jerry, J., Gordon, J. I., Landschultz, W. H., and McKnight, S. L. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev., 3: 1146-1156, 1989.
38. Alam, T., Au, M. R., and Papaconstinon, J. Differential expression of three C/EBP isoforms in multiple tissues during the acute phase response. J. Biol. Chem., 267: 5021-5024, 1992.
39. Xu, X. M., Sansores-Garcia, L., Chen, X. M., Matijevic-Aleksic, N., Du, M, and Wu, K. K. Suppression of inducible cyclooxygenase-2 gene transcription by aspirin and sodium salicylate. Proc. Natl. Acad. Sci. USA, 96: 5292-5297, 1999.
40. Fujita, T., Marsui, M., Takaku, K., Uetake, H., Ichikawa, W., Taketo, M., and Sugihara, K. Size-and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res., 58: 4823-4826, 1998.
41. Subbaramaiah, K., Telang, N., Ramonetti, J. T., Araki, R., DeVito, B., Weksler, B. B., and Dannenberg, A. J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res., 56: 4424-4429, 1996.
42. Subbaramiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., Jang, M., Pezzuto, J. M., and Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 273: 21875-21882, 1998.
43. Ristimaki, A., Honkanen, N., Jankala, H., Sipponen, P., and Harkonen, M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res., 57: 1276-1280, 1997.
44. Parett, M. L., Harris, R. E., Joarder, F. S., Ross, M. S., Claussen, K. P., and Robertson, F. M. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol., 10: 503-507, 1997.
45. Kargman, S., O'Neill, G., Vickers, P., Evans, J., Mancini, J., and Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55: 2556-2559, 1995.
46. Vogelstein, B., Fearson, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smiths, A. M. M., and Bos, J. L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319: 525-532, 1988.
47. Fearson, E. R. Human cancer syndromes: clues to the origin and nature of cancer. Science (Washington DC), 278: 1043-1050, 1997.
48. Kinzler, K. W., and Vogelstein, B. Lessons from hereditary colorectal cancer. Cell, 87: 159-170, 1996.
49. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412, 1998.
50. Bennett, A. The production of prostanoids in human cancers and their implications for tumor progression. Prog. Lipid Res., 25: 539-542, 1986.
51. Rolland, P. H., Martin, P. M., Jacquemier, J., Rolland, A. M., and Toga, M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst., 64: 1061-1070, 1980.
52. Jung, T. T. K., Berlinger, N. T., and Juhn, S. K. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope, 95: 307-312, 1985.
53. Lupulescu, A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot. Essent. Fatty Acids, 54: 83-94, 1996.
54. Zimmermann, K. C., Sabia, M., Weber, A., Borchard, F., Gabbert, H. E., and Sehror, K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res., 59; 198-204, 1999.
55. Ben-Av, P., Crofford, L. J., Wilder, R. L., and Hla, T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett., 372: 83-87, 1995.
56. 2 in human colon cancer cells. Cancer Res., 58: 362-366, 1998.
57. Goodwin, J. S., and Ceuppens, J. Regulation of immune response by prostaglandins. J. Clin. Immunol., 3: 295-314, 1983.
58. Tsujii, M., and DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493-501, 1995.
59. Williams, C. S., Smalley, W., and DuBois, R. N. Aspirin use and potential mechanisms for colorectal cancer prevention. J. Clin. Investig., 100: 1325-1329, 1997.
60. Mestre, J. R., Subbaramaiah, K., Sacks, P. G., Schantz, S. P., Tanabe, T., Inoue, H., and Dannenberg, A. J. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res., 57: 1081-1085, 1997.
61. Hamilton, L. C., Mitchell, J. A. Tomlinson, A. M., and Warner, T. D. Synergy between cyclooxygenase-2 induction and arachidonic acid supply in rivo: consequences for nonsteroidal antiinflammatory drug efficacy. FASEB J., 13: 245-251, 1999.
62. 2 to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Commun., 196: 147-153, 1993.
63. 2 from cytosol to the nuclear envelope in rat basophilic leukemic cells stimulated with calcium ionophore or IgE/antigen. J. Biol. Chem., 270: 15359-15365, 1995.
64. 2 to the nuclear envelope and endoplasmic reticulum. J. Biol. Chem., 270; 30749-30756, 1995.
65. Morita, I., Schindler, M., Regier, M. K., Otto, J. C., Hori, T., DeWitt, D. L., and Smith, W. L. Different intracellular locations for prostaglandin endoperoxidase H synthase-1 and -2. J. Biol. Chem., 270: 10902-10908, 1995.
66. Murakami, M., Matsumoto, R., Austen, K. F., and Arm, J. P. Prostaglandin endoperoxide synthase-l and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J. Biol. Chem., 269: 22269-22276, 1994.
67. Meade, E. A., Smith, W. L., and DeWitt, D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J. Biol. Chem., 268: 6610-6615, 1993.
68. Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., and Vane, J. R. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA, 90: 11693-11699, 1994.
69. Peri, K. G., Hardy, P., Li, D. Y., Varma, D. R., and Chemtob, S. Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandin in the newborn. J. Biol. Chem., 270: 24615-24651, 1995.